---
layout: default
title: Sevoflurane
parent: 僅模型預測 (L5)
nav_order: 307
evidence_level: L5
indication_count: 10
---

# Sevoflurane
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sevoflurane: From General Anesthesia to Prinzmetal Angina

## One-Sentence Summary

Sevoflurane is a fluorinated volatile inhalation agent widely used for the induction and maintenance of general anesthesia in surgical settings.
The TxGNN model predicts it may be effective for **Prinzmetal Angina** (vasospastic angina),
with **0 clinical trials** and **0 publications** currently supporting this direction — making this a model-only prediction at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Inhalation general anesthetic (not formally registered in the Philippines; 0 active licenses on record) |
| Predicted New Indication | Prinzmetal Angina |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on known pharmacological class information, Sevoflurane is a halogenated ether inhalation anesthetic that produces general anesthesia through multiple ion channel effects — including enhancement of GABA-A receptor activity, inhibition of NMDA receptors, and activation of ATP-sensitive potassium (K\_{ATP}) channels.

The K\_{ATP} channel activation pathway is the key link to Prinzmetal angina. Sevoflurane's activation of coronary vascular K\_{ATP} channels promotes coronary artery vasodilation and triggers ischemic preconditioning — a cardioprotective phenomenon that theoretically counteracts the pathological coronary artery spasm underlying Prinzmetal angina. This is a mechanistically plausible, though indirect, connection.

However, the clinical translation pathway is critically limited. Sevoflurane is exclusively an inhalation agent requiring specialized vaporizer equipment and monitored anesthesia conditions. Prinzmetal angina is a chronic episodic condition requiring either acute rescue or long-term prophylactic therapy — neither of which is achievable with an inhaled anesthetic. The mechanistic link exists on paper, but the route of administration poses an insurmountable practical barrier to repurposing.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Sevoflurane in Prinzmetal Angina.

---

## Literature Evidence

Currently no related literature available for Sevoflurane in Prinzmetal Angina.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is a purely model-driven prediction (L5) with zero supporting clinical trials or literature. While the K\_{ATP} channel mechanism provides a theoretical link to coronary vasospasm, the fundamental incompatibility between inhalation-only delivery and chronic angina management makes clinical translation not feasible without a radically different drug formulation.

**To proceed, the following is needed:**
- Detailed MOA data from DrugBank (DG002) to confirm K\_{ATP} channel involvement
- TFDA/Philippines FDA package insert to retrieve formal warnings and contraindications (DG001)
- A credible alternative delivery concept (e.g., inhaled sevoflurane as acute abort therapy for refractory vasospastic episodes in a monitored setting) before any research pathway can be proposed
- Literature search specifically targeting volatile anesthetics + coronary vasospasm + ischemic preconditioning to determine whether any translational case reports exist outside this dataset's capture window

---

> ⚠️ **Disclaimer:** This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

